Clinical Trial Detail

NCT ID NCT02351739
Title Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

bladder urothelial carcinoma

urinary bladder cancer

Therapies

Pembrolizumab

Acalabrutinib

Age Groups: adult

No variant requirements are available.